Startseite
Impressum
Datenschutz
 
 
  SPOT ON
 

Oseltamivir (TAMIFLU): benefit of the neuraminidase inhibitor remains unclear

 
  NEW ON THE MARKET
 

Dexamfetamine (ATTENTIN) for attention deficit hyperactivity disorder?

Azilsartan (EDABRI) - angiotensin II receptor blocker no. 8

 
  a-t READER'S QUESTIONS AND COMMENTS
 

Perioperative management of patients with coronary heart disease taking acetylsalicylic acid

Does anticoagulation for atrial fibrillation protect against myocardial infarction?

Do sulfonylureas increase mortality?

What´s new on SINUPRET?

 
  IN BRIEF
 

Placebo refused - how independent research is thwarted

 
  CURRENT ADR NETWORK REPORT

Cancer due to liraglutide (VICTOZA)?

 
  SIDE EFFECTS
 

Update: progressive leukoencephalopathy due to natalizumab (TYSABRI)

Consequences of deaths with multiple sclerosis drug fingolimod (GILENYA)

 
© arznei-telegramm 2/2012